PS Rastogi
19 Papers
6 Citations
PS Rastogi is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 7 publications.
Chat about Author
Papers
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
Charles E. Geyer,Judy Garber,R. D. Gelber,Greg Yothers,M Taboada,Louetta A. Ross,PS Rastogi,Karen Y. Cui,Amal Arahmani,Gursel Aktan,A. Armstrong,Monica Arnedos,Judith Balmaña,Joop P. W. van den Bergh,J. Bliss,S. Delaloge,S. Domchek,Andrea Eisen,F. Elsafy,Luis Fein,Anitra Fielding,James M. Ford,S. Friedman,Karen A. Gelmon,L. Gianni,Michael Gnant,Simon J. Hollingsworth,Sa Im,Agnes Jager,Oskar T. Johannsson,Sunil R. Lakhani,Wolfgang Janni,Barbro Linderholm,T-W. Liu,Niklas Loman,Larissa A. Korde,S. Loibl,P. Lucas,Frederik Marmé,Eduardo Martínez de Dueñas,Robin McConnell,Kelly-Anne Phillips,Martine Piccart,Giovanna Rossi,R. K. Schmutzler,Elżbieta Senkus,Z Shao,Paramananda Dash Sharma,C. Singer,Tanja Spanic,Elmar Stickeler,Masakazu Toi,TA Traina,Giuseppe Viale,Gabriele Zoppoli,Y. Park,Rinat Yerushalmi,H Yang,Dan-mei Pang,KH Jung,A. Mailliez,Zusen Fan,Isabelle Tennevet,G. Q. Zhang,Tauana Nagy,GS Sonke,Q. Sun,Marina Parton,Marco Colleoni,M. Schmidt,Adam Brufsky,Wajeeha Razaq,Bela Kaufman,D. Cameron,Carolyn Campbell,A. Tutt +75 more
TL;DR: The randomized OlympiA trial as discussed by the authors compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in BRCA1/2pv and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer.
261
Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
Hope S. Rugo,Joyce O'Shaughnessy,Frances M. Boyle,Masakazu Toi,Reuben James Broom,I. Blancas,Mahmut Gumus,Tetsumasa Yamashita,Y. H. Im,PS Rastogi,Flora Zagouri,C. Song,M. Campone,Belen San Antonio,Ashwin Shahir,Maarten Hulstijn,S. Zimmermann,Ran Wei,S. Johnson,Mattea Reinisch,Sara M. Tolaney +20 more
TL;DR: Abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone as discussed by the authors .
72
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Nadia Harbeck,PS Rastogi,John W. O’Shaughnessy,F. Boyle,J. Cortés,H.S. Rugo,Matthew P. Goetz,E.P. Hamilton,E. Senkus-Konefka,A. Tryakin,P. Neven,J. Huober,R.J. Wei,V. Andre,M. Muñoz,B. San Antonio,Ashwin Shahir,M. Martin Jimenez,S.R.D. Johnston +18 more
TL;DR: Abemaciclib plus endocrine therapy significantly improved invasive disease-free survival and distant relapse-free survival in high-risk early breast cancer patients, with sustained benefits at 5 years, including a 7.6% absolute improvement in invasive disease-free survival rates.
12
354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)
E. Hamilton,S. Loibl,N. Niikura,PS Rastogi,K.S. Saini,I. Gioni,T. Klinowska,I. Mayer,M. Stuart,E. Syta,A. Walding,T. Bachelot +11 more
TL;DR: This phase III study (CAMBRIA-1) evaluates extended adjuvant therapy with camizestrant vs standard endocrine therapy in ER+/HER2– early breast cancer patients with intermediate or high risk of recurrence, aiming to improve invasive breast cancer-free survival.
2